Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2009-09-21 Investor Presentation
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Rodman&Renshaw Healthcare Conference, September 10, 2009
Investor Presentation Classification · 98% confidence The document is titled 'Rodman & Renshaw Annual Global Investment Conference' and is dated September 10, 2009. It contains forward-looking statements, financial highlights (though heavily garbled in the table), pipeline updates, and detailed descriptions of drug programs (MOR103, MOR202, etc.) presented in a slide-deck format. This structure—a presentation given at an investment conference detailing strategy, pipeline, and recent developments—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, a standalone Audit Report (AR), or a brief Earnings Release (ER).
2009-09-21 English
Sal. Oppenheim Healthcare Conference Aug 31, 2009
Investor Presentation Classification · 98% confidence The document is titled 'Sal. Oppenheim European Healthcare Investors Conference' and is dated 'August 31, 2009'. It contains slides detailing a company's product pipeline, clinical trial progress (MOR103 Phase I, MOR202 program), business segments (AbD Serotec), and financial guidance for 2009. This structure—a presentation given at an investor conference detailing strategy, pipeline, and financials—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an ER, nor is it a transcript of a call, but rather a prepared presentation deck.
2009-09-11 English
Q2 Bericht 2009
Interim / Quarterly Report Classification · 100% confidence The document is a '2. Zwischenbericht' (Second Interim Report) for the period January to June 2009 for MorphoSys. It contains comprehensive financial statements (Income Statement, Balance Sheet, Cash Flow, etc.) prepared under IFRS, along with a management discussion and analysis (Konzern-Zwischenlagebericht). Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2009
2009-07-29 German
Q2 Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MorphoSys Group: 2nd Interim Report January – June 2009' and contains comprehensive financial statements (Consolidated Statement of Operations, Balance Sheet, Cash Flows) and management discussion and analysis for a six-month period. It is clearly an interim financial report, not an announcement or a summary, and meets the criteria for the 'IR' category. H1 2009
2009-07-29 English
Presentation at the AGM 2009
AGM Information Classification · 98% confidence The document explicitly mentions 'Annual Shareholders' Meeting 2009' at the beginning and includes sections like 'Operational Review 2008', 'Financial Review 2008 & Q1 2009', 'Information on the Agenda', and 'Voting'. This structure, combined with the date of the meeting (May 13, 2009), strongly indicates that the material is related to the Annual General Meeting (AGM). Although it contains financial data (Consolidated Statements of Operations), the primary context and framing are for the shareholder meeting presentation, not a formal regulatory filing like a 10-K or a standalone Interim Report (IR). Therefore, the most appropriate classification is AGM Information.
2009-06-25 English
Hauptversamlung 2009 - Präsentation des Vorstands
AGM Information Classification · 98% confidence The document text is titled "Hauptversammlung 2009" (Annual General Meeting 2009) and explicitly lists sections like "Informationen zur Tagesordnung" (Information on the Agenda), "Wortmeldungen" (Speeches/Statements), and "Abstimmung" (Voting). It also details management changes and operational/financial reviews relevant to the meeting. This content strongly indicates materials presented or discussed at an Annual General Meeting. Therefore, the classification should be AGM-R (AGM Information). The document is comprehensive, suggesting it is the material itself, not just an announcement of the meeting.
2009-06-25 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.